Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

References

• KatelarisCHBieloryLEvidence-based study design in ocular allergy trialsCurr Opin Allergy Clin Immunol20088548448818769206
   PubMed Web of Science ®Google Scholar
• del CuvilloASastreJMontoroJAllergic conjunctivitis and H1 antihistaminesJ Investig Allergol Clin Immunol200919Suppl 11118
   Google Scholar
• JohanssonSGBieberTDahlRRevised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003J Allergy Clin Immunol2004113583283615131563
   PubMed Web of Science ®Google Scholar
• ChigbuDIThe management of allergic eye diseases in primary eye careCont Lens Anterior Eye200932626027219879797
   PubMed Web of Science ®Google Scholar
• VirchowJCKaySDemolyPMullolJCanonicaWHigginsVImpact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients – an observational, cross sectional study in four countries in EuropeJ Med Econ201114330531421488807
   PubMedGoogle Scholar
• BlaissMSAllergic rhinoconjunctivitis: burden of diseaseAllergy Asthma Proc200728439339717883905
   PubMed Web of Science ®Google Scholar
• UchioETreatment of allergic conjunctivitis with olopatadine hydrochloride eye dropsClin Ophthalmol20082352553119668750
   PubMedGoogle Scholar
• AzariAABarneyNPConjunctivitis: a systematic review of diagnosis and treatmentJAMA2013310161721172924150468
   PubMed Web of Science ®Google Scholar
• YanniJMWeimerLKSharifNAXuSXGamacheDASpellmanJMInhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugsArch Ophthalmol1999117564364710326962
   PubMedGoogle Scholar
• AbelsonMBGomesPJVogelsonCTClinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental studyClin Ther20042681237124815476905
   PubMed Web of Science ®Google Scholar
• AbelsonMBSpanglerDLEpsteinABMahFSCramptonHJEfficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challengeCurr Eye Res200732121017102218085465
   PubMed Web of Science ®Google Scholar
• AguilarAJComparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarateActa Ophthalmol Scand Suppl2000230525511057352
   PubMedGoogle Scholar
• ArtalMNLunaJDDiscepolaMA forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%Acta Ophthalmol Scand Suppl2000230646511057355
   PubMedGoogle Scholar
• BerdyGJSpanglerDLBenschGBerdySSBrusattiRCA comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge modelClin Ther200022782683310945509
   PubMed Web of Science ®Google Scholar
• BrockmanHLMomsenMMKnudtsonJRMillerSTGraffGYanniJMInteractions of olopatadine and selected antihistamines with model and natural membranesOcul Immunol Inflamm200311424726814704897
   PubMed Web of Science ®Google Scholar
• KatelarisCHCiprandiGMissottenLTurnerFDBertinDBerdeauxGA comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitisClin Ther200224101561157512462286
   PubMed Web of Science ®Google Scholar
• LanierBQFinegoldID’ArienzoPGranetDEpsteinABLedgerwoodGLClinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge modelCurr Med Res Opin20042081227123315324525
   PubMed Web of Science ®Google Scholar
• LichtensteinSJPasquineTAEdwardsMRWellsDTGrossRDRobertsonSMSafety and tolerability of olopatadine 0.2% in children and adolescentsJ Ocul Pharmacol Ther200723436637117803435
   PubMed Web of Science ®Google Scholar
• MahFSRosenwasserLJTownsendWDGreinerJVBenschGEfficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challengeCurr Med Res Opin20072361445145217559743
   PubMed Web of Science ®Google Scholar
• OhnoSA multicenter, double-masked, randomized evaluation of olopatadine 0.2% using the conjunctival allergen challenge model in Japanese patients with allergic conjunctivitisNihon Ganka Gakkai Zasshi20121161211231129 Japanese23379201
   PubMedGoogle Scholar
• OhnoSAndoMA 10-week safety and efficacy evaluation of olopatadine, 0.2% instilled twice-daily in patients with allergic conjunctivitis in JapanNihon Ganka Gakkai Zasshi20121169869879 Japanese23092094
   PubMedGoogle Scholar
• RosenwasserLJMahrTAbelsonMBGomesPJKennedyKA comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitisAllergy Asthma Proc200829664465319063816
   PubMed Web of Science ®Google Scholar
• ScoperSVBerdyGJLichtensteinSJPerception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitisAdv Ther20072461221123218165204
   PubMed Web of Science ®Google Scholar
• SpanglerDLBenschGBerdyGJEvaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge modelClin Ther20012381272128011558863
   PubMed Web of Science ®Google Scholar
• VogelsonCTAbelsonMBPasquineTPreclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administrationAllergy Asthma Proc2004251697515055565
   PubMed Web of Science ®Google Scholar
• YaylaliVDemirlenkITatlipinarSComparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitisActa Ophthalmol Scand200381437838212859265
   PubMedGoogle Scholar
• GamacheDAAlaniLGhoshMGalánFJPerdiguerNSinghOinventorsAlcon Research Ltd, assigneeHigh concentration olopatadine ophthalmic compositionWorld Intellectual Property Organization patentWO201215906420121122
   Google Scholar
• AbelsonMBLoefferOConjunctival allergen challenge: models in the investigation of ocular allergyCurr Allergy Asthma Rep20033436336812791217
   PubMed Web of Science ®Google Scholar
• AbelsonMBChambersWASmithLMConjunctival allergen challenge. A clinical approach to studying allergic conjunctivitisArch Ophthalmol1990108184882297337
   PubMed Web of Science ®Google Scholar
• World Medical AssociationWorld Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjectsJAMA2013310202191219424141714
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationDermatologic and Ophthalmic Drugs Advisory Committee meeting briefing document: Bepreve™ (bepotastine besilate ophthalmic solution) 1.5%2009 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM170900.pdfAccessed May 13, 2015
   Google Scholar
• US Food Drug AdministrationStatistical review and evaluation: alcaftadine ophthalmic solution 0.25%2009 Available from: http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm223818.pdfAccessed May 13, 2015
   Google Scholar
• US Food Drug AdministrationClinical review of NDA 2062762014 Available from: http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm434580.pdfAccessed May 13, 2015
   Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• RichterAAntonSEKochPDennettSLThe impact of reducing dose frequency on health outcomesClin Ther20032582307233514512137
   PubMed Web of Science ®Google Scholar
• AbelsonMBGomesPJPasquineTEdwardsMRGrossRDRobertsonSMEfficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitisAllergy Asthma Proc200728442743317883910
   PubMed Web of Science ®Google Scholar